Proliferation Signatures and Prognosis for Gastrointestinal Cancer

• US 20110086349A1
• Filed: 04/05/2010
• Published: 04/14/2011
• Est. Priority Date: 10/05/2007
• Status: Abandoned Application

• Current Assignee: Pacific Edge Ltd.
• Original Assignee: Pacific Edge Ltd.
• Inventors: Lin, Yu-Hsin, Anjomshoaa, Ahmad, Black, Michael A., Reeve, Anthony Edmund
• Application Number:
  US12/754,077
• Publication Number:
  US 20110086349A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/118 Prognosis of disease development
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: C12Q 2600/16 Primer sets for multiplex assays
• CPC Class Codes: G01N 2800/60 Complex ways of combining multiple protein biomarkers for diagnosis
• CPC Class Codes: G01N 33/57419 of colon
• CPC Class Codes: G01N 33/57446 of stomach or intestine

Abstract

This invention relates to methods and compositions for determining the prognosis of cancer in a patient, particularly for gastrointestinal cancer, such as gastric or colorectal cancer. Specifically, this invention relates to the use of genetic markers for the prediction of the prognosis of cancer, such as gastric or colorectal cancer, based on cell proliferation signatures. In various aspects, the invention relates to a method of predicting the likelihood of long-term survival of a cancer patient, a method of determining a treatment regime for a cancer patient, a method of preparing a personalized genomics profile for a cancer patient, among other methods as well as kits and devices for carrying out these methods.

Claims

3. A method of predicting the likelihood of long-term survival of a gastrointestinal cancer patient without the recurrence of gastrointestinal cancer, comprising determining the expression level of one or more prognostic RNA transcripts or their expression products in a gastrointestinal sample obtained from the patient, normalized against the expression level of all RNA transcripts or their products in the gastrointestinal cancer tissue sample, or of a reference set of RNA transcripts or their expression products;

wherein the prognostic RNA transcript is the transcript of one or more genes selected from table A, Table B, Table C or Table D; and

establishing likelihood of long-term survival without gastrointestinal cancer recurrence.

4. The method of claim 3, wherein at least one prognostic RNA transcripts or its expression products is selected from any one of CDC2, MCM6, RPA3, MCM7, PCNA, G22P1, KPNA2, ANLN, APG7L, TOPK, GMNN, RRM1, CDC45L, MAD2L1, RAN, DUT, RRM2, CDK7, MLH3, SMC4L1, CSPG6, POLD2, POLE2, BCCIP, Pfs2, TREX1, BUB3, FEN1, DRF1, PREI3, CCNE1, RPA1, POLE3, RFC4, MCM3, CHEK1, CCND1, and CDC37

5. The method of claim 3 comprising determining the expression level of at least two, at least five, at least 10, or at least 15 of the prognostic RNA transcripts or their expression products.

6. The method according to claim 3, wherein increased expression of the one or more prognostic RNA transcripts or their expression products indicates an increased likelihood of long-term survival without gastrointestinal cancer recurrence.

7. The method according to claim 3, wherein a predictive model is applied, established by applying a predictive method to expressions levels of the predictive signature in recurrent and non-recurrent tumour samples, to establishing likelihood of long-term survival without gastrointestinal cancer recurrence.

8. The method of claim 7, wherein said predictive method is selected from the group consisting of linear models, support vector machines, neural networks, classification and regression trees, ensemble learning methods, discriminant analysis, nearest neighbor method, bayesian networks, independent components analysis.

9. The method of claim 3 wherein the gastrointestinal cancer is gastric cancer or colorectal cancer.

10. The method of claim 3 wherein the expression level of one or more prognostic RNA transcripts is determined.

11. The method of claim 3 wherein the RNA is isolated from a fixed, wax- embedded gastrointestinal cancer tissue specimen of the patient.

12. The method of claim 3 wherein the RNA is isolated from core biopsy tissue or fine needle aspirate. cells.

45. A kit comprising one pr more of (1) extraction buffer/reagents and protocol;

(2) reverse transcription buffer/reagents and protocol; and

(3) quantitative RT-PCR buffer/reagents and protocol suitable for performing the method of any one of claims claim claims 3.

13. An array comprising polynucleotides hybridizing to two or more genes selected from table A, Table B, Table C or Table D.

14. An array of claim 13 comprising polynucleotides hybridizing to two or more of the following genes:

CDC2, MCM6, RPA3, MCM1, PCNA, G22P1, KPNA2, ANLN, APG7L, TOPK, GMNN, RRM1, CDC45L, MAD2L1, RAN, DUT, RRM2, CDK7, MLH3, SMC4L1, CSPG6, POLD2, POLE2, BCCIP, Pfs2, TREX1, BUB3, FEN1, DRF1, PREI3, CCNE1, RPA1, POLE3, RFC4, MCM3, CHEK1, CCND1, and CDC37.

15. The array of claim 13 comprising polynucleotides hybridizing to at least 3, at least five, at least 10 or at least 15 of the genes.

16. The array of claim 13 comprising polynucleotides hybridizing to the following genes:

CDC2, MCM6, RPA3, MCM1, PCNA, G22P1, KPNA2, ANLN, APG7L, TOPK, GMNN, RRM1, CDC45L, MAD2L1, RAN, DUT, RRM2, CDK7, MLH3, SMC4L1, CSPG6, POLD2, POLE2, BCCIP, Pfs2, TREX1, BUB3, FEN1, DRF1, PREI3, CCNE1, RPA1, POLE3, RFC4, MCM3, CHEK1, CCND1, and CDC37.

17. The array of claim 13 wherein the polynucleotides are cDNAs.

18. The array of claim 17 wherein the cDNAs are about 500 to 5000 bases long.

19. The array of claim 13 wherein the polynucleotides are oligonucleotides.

20. The array of claim 19 wherein the oligonucleotides are about 20 to 80 bases long.

21. The array ofclaim 13 wherein the solid surface is glass.

22. A method of predicting the likelihood of long-term survival of a patient diagnosed with gastrointestinal cancer, without the recurrence of gastrointestinal cancer, comprising the steps of:

(1) determining the expression levels of the RNA transcripts or the expression products of genes or a gene selected from table A, Table B, Table C or Table D, in a gastrointestinal cancer tissue sample obtained from the patient, normalized against the expression levels of all RNA transcripts or their expression products in the gastrointestinal cancer tissue sample, or of a reference set of RNA transcripts or their products;

(2) subjecting the data obtained in step (1) to statistical analysis; and

(3) determining whether the likelihood of the long-term survival has increased or decreased;

and establishing the likelihood of long-term survival without gastrointestinal cancer recurrence.

1. A prognostic signature for determining progression of gastrointestinal cancer in a patient, comprising one or more genes selected from Table A, Table B, Table C or Table D.

2. The signature of claim 1, wherein the signature comprises one or more genes selected from any one of CDC2, MCM6, RPA3, MCM7, PCNA, G22P1, KPNA2, ANLN, APG7L, TOPK, GMNN, RRM1, CDC45L, MAD2L1, RAN, DUT, RRM2, CDK7, MLH3, SMC4L1, CSPG6, POLD2, POLE2, BCCIP, Pfs2, TREX1, BUB3, FEN1, DRF1, PREI3, CCNE1, RPA1, POLE3, RFC4, MCM3, CHEK1, CCND1, and CDC37.

23. The method of claim 22, wherein at least one prognostic RNA transcripts or its expression products is selected from any one CDC2, MCM6, RPA3, MCM1, PCNA, G22P1, KPNA2, ANLN, APG7L, TOPK, GMNN, RRM1, CDC45L, MAD2L1, RAN, DUT, RRM2, CDK7, MLH3, SMC4L1, CSPG6, POLD2, POLE2, BCCIP, Pfs2, TREX1, BUB3, FEN1, DRF1, PREI3, CCNE1, RPA1, POLE3, RFC4, MCM3, CHEK1, CCND1, and CDC37.

24. The method of claim 22 wherein the statistical analysis is performed by using the Cox Proportional Hazards model.

25. A method of preparing a personalized genomics profile for a cancer patient, comprising the steps of (a) subjecting RNA extracted from a gastrointestinal tissue obtained from the patient to gene expression analysis;

(b) determining the expression level of one or more genes selected from the gastrointestinal cancer gene set listed in any one of Table A, Table 13, Table C or Table D, wherein the expression level is normalized against a control gene or genes and optionally is compared to the amount found in a gastrointestinal cancer reference tissue set; and

(c) creating a report summarizing the data obtained by the gene expression analysis.

26. The method of claim 24 wherein the gastrointestinal tissue is obtained from a fixed, paraffin-embedded biopsy sample.

27. The method of claim 26 wherein the RNA is fragmented.

28. The method of claim 22 wherein the report includes prediction of the likelihood of long term survival of the patient.

29. The method of claim 22 wherein the report includes recommendation for a treatment modality of the patient.

25-1. The method of claim 24, wherein the gastrointestinal tissue comprises gastrointestinal cancer cells.

30. A prognostic method comprising:

(a) subjecting a sample comprising gastrointestinal cancer cells obtained from a patient to quantitative analysis of the levels of RNA transcripts of at least one gene selected from any one of Table A, Table B, Table C or table D, or its product, and (b) identifying the patient as likely to have an increased likelihood of long-term survival without gastrointestinal cancer recurrence if normalized expression levels of the gene or genes, or their products, are elevated above a defined expression threshold.

31. The method of claim 30, wherein at least one prognostic RNA transcripts or its expression products is selected from any one CDC2, MCM6, RPA3, MCM1, PCNA, G22P1, KPNA2, ANLN, APG7L, TOPK, GMNN, RRM1, CDC45L, MAD2L1, RAN, DUT, RRM2, CDK7, MLH3, SMC4L1, CSPG6, POLD2, POLE2, BCCIP, Pfs2, TREX1, BUB3, FEN1, DRF1, PREI3, CCNE1, RPA1, POLE3, RFC4, MCM3, CHEK1, CCND1, and CDC37.

32. The method of claim 30, wherein the levels of the RNA transcripts of the genes are normalized relative to the mean level of the RNA transcript or the product of two or more housekeeping genes.

33. The method of claim 32 wherein the housekeeping genes are selected from the group consisting of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), Cypl, albumin, actins, tubulins, cyclophilin hypoxantine phosphoribosyltransferase (HRPT), L32, 28S, and 185.

34. The method of claim 30 wherein the sample is subjected to global gene expression analysis of all genes present above the limit of detection.

35. The method of claim 30 wherein the levels of RNA transcripts of the genes are normalized relative to the mean signal of the RNA transcripts or the products of all assayed genes or a subset thereof.

36. The method of claim 30 wherein the levels of RNA transcripts are determined by quantitative RT-PCR, and the signal is a Ct value.

37. The method of claim 35 wherein the assayed genes include at least 50 or at least 100 cancer related genes.

38. The method of claim 30 wherein the patient is human.

39. The method of claim 30 wherein the sample is a fixed, paraffin-embedded tissue (FPET) sample, or fresh or frozen tissue sample.

40. The method of claim 30 wherein the sample is a tissue sample from fine needle, core, or other types of biopsy.

41. The method of claim 30 wherein the quantitative analysis is performed by quantitative RT-PCR.

42. The method of claim 30 wherein the quantitative analysis is performed by quantifying the products of the genes.

43. The method of claim 30 wherein the products are quantified by immunohistochemistry or by proteomics technology.

44. The, method of claim 30 further comprising the step of preparing a report indicating that the patient has an increased likelihood of long-term survival without gastrointestinal cancer recurrence.